首页> 外文期刊>Journal of the European Academy of Dermatology and Venereology: JEADV >Decongestion improves cell-mediated immunity in postmastectomy arm lymphoedema: A pilot study
【24h】

Decongestion improves cell-mediated immunity in postmastectomy arm lymphoedema: A pilot study

机译:消脂改善乳房切除术后手臂淋巴水肿中的细胞介导的免疫:一项初步研究

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background Chronic lymphoedematous limbs have an increased propensity for infections and primary or secondary malignant tumours. It has been attributed to suppressed delayed-type hypersensitivity measured in lymphoedemas related to Stewart-Treves syndrome, Kaposi's sarcoma or breast cancer treatment. Cell-mediated immunity is an effective defence mechanism against bacteria, fungi, viruses and tumour cells. Objective We aimed to examine whether decongestive lymphoedema therapy could improve cell-mediated immunity in breast cancer treatment-related lymphoedema (BCRL). Methods Eight women with unilateral BCRL were included in this study. At baseline, tuberculin skin test (TST) was performed on the volar surfaces of the forearms of the affected and non-affected sides using 0.5, 1 and 5 tuberculin units in the form of three consecutive injections with 3-cm spaces in-between, and arm volumes were measured using the Kuhnke's disc model. Decongestive lymphatic therapy was given to swollen arms in 10 consecutive working days. At the end of intensive decongestion, TST on affected side and bilateral volumetry were repeated. Results Baseline test using undiluted (5 units) and fivefold diluted (1 unit) tuberculin solutions has shown significant differences (P < 0.05) between the mean sizes (11.81 ± 2.32 and 7.75 ± 1.92; 7.12 ± 1.12 and 5.12 ± 0.91 respectively) in favour to healthy arms. Post therapeutically, the mean sizes were significantly increased (P < 0.05) in the dilutions of 1: 1 and 1: 5 (7.75 ± 1.92 and 10.56 ± 1.23 mm, 5.12 ± 0.91 and 5.93 ± 1.74 mm respectively). Conclusion Significant increase in TST sizes suggests that decongestive lymphatic therapy is able to partially restore impaired cellular immune function in BCRL.
机译:背景慢性淋巴水肿的肢体感染和原发性或继发性恶性肿瘤的患病率增加。它被归因于在与Stewart-Treves综合征,卡波济氏肉瘤或乳腺癌治疗相关的淋巴水肿中测得的迟发型超敏反应受到抑制。细胞介导的免疫是针对细菌,真菌,病毒和肿瘤细胞的有效防御机制。目的我们旨在研究充血性淋巴水肿治疗能否提高乳腺癌治疗相关性淋巴水肿(BCRL)的细胞介导的免疫力。方法纳入八名单侧BCRL女性。基线时,使用0.5、1和5个结核菌素单位,以连续3次注射的形式,在患处和未患病侧的前臂掌侧表面上进行结核菌素皮肤测试(TST),两次注射之间的间隔为3厘米,和手臂的体积是使用Kuhnke的圆盘模型测量的。在连续的10个工作日中对肿胀的手臂进行消肿性淋巴治疗。严重的充血结束时,在患侧和双侧容积中反复进行TST。结果使用未稀释(5单位)和五倍稀释(1单位)的结核菌素溶液进行的基线测试显示,平均大小之间分别存在显着差异(P <0.05)(11.81±2.32和7.75±1.92; 7.12±1.12和5.12±0.91)。支持健康的武器。治疗后,在1:1和1:5的稀释度中,平均大小显着增加(P <0.05)(分别为7.75±1.92和10.56±1.23 mm,5.12±0.91和5.93±1.74 mm)。结论TST大小的显着增加表明,充血性淋巴治疗可以部分恢复BCRL细胞免疫功能受损。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号